Literature DB >> 24868087

The Cebpa +37-kb enhancer directs transgene expression to myeloid progenitors and to long-term hematopoietic stem cells.

Hong Guo1, Ou Ma1, Alan D Friedman2.   

Abstract

C/EBPα is expressed preferentially in myeloid compared with lymphoid or erythroid cells and directs myeloid lineage specification. C/EBPα is also expressed at lower levels in HSCs and in several nonhematopoietic tissues. The Cebpa gene has a conserved, 450-bp segment at +37 kb that harbors enhancer-specific epigenetic marks and is activate in a myeloid cell line. Herein, we characterize transgenic C57BL/6 mice, in which the Cebpa enhancer and 845-bp promoter regulate a hCD4 reporter. FACS analysis, in vitro colony assays, and in vivo competitive and secondary transplantation revealed that myeloid but not MEPs or lymphoid progenitors and also functional LT-HSCs are found almost exclusively in the Cebpa-hCD4(+) compared with hCD4(-) marrow population. hCD4(+) CMP yielded predominantly myeloid, whereas hCD4(-) CMP generated mainly Meg/E colonies. Providing insight into control of CMP maturation, Cebpa and Pu.1 RNAs were preferentially expressed in hCD4(+) CMP, Scl, Gata2, Gata1, Klf1, Ets1, and Fli1 predominated in hCD4(-) CMP, and Runx1, Myb, HoxA9, and Erg levels were similar in both. Cebpa-hCD4 transgene expression was lacking in multiple nonhematopoietic tissues. In summary, the +37-kb Cebpa enhancer and promoter are sufficient for marrow myeloid progenitor and LT-HSC-specific expression.
© 2014 Society for Leukocyte Biology.

Entities:  

Keywords:  differentiation; hematopoiesis; myelopoiesis

Mesh:

Substances:

Year:  2014        PMID: 24868087      PMCID: PMC4138201          DOI: 10.1189/jlb.2AB0314-145R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  19 in total

1.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages.

Authors:  K Akashi; D Traver; T Miyamoto; I L Weissman
Journal:  Nature       Date:  2000-03-09       Impact factor: 49.962

2.  The potential benefits of insulators on heterologous constructs in transgenic animals.

Authors:  Patricia Giraldo; Sylvie Rival-Gervier; Louis-Marie Houdebine; Lluís Montoliu
Journal:  Transgenic Res       Date:  2003-12       Impact factor: 2.788

3.  CCAAT/enhancer binding protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 preadipocytes.

Authors:  R J Christy; K H Kaestner; D E Geiman; M D Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment.

Authors:  S Ogilvy; D Metcalf; L Gibson; M L Bath; A W Harris; J M Adams
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

5.  Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha.

Authors:  Pu Zhang; Junko Iwasaki-Arai; Hiromi Iwasaki; Maris L Fenyus; Tajhal Dayaram; Bronwyn M Owens; Hirokazu Shigematsu; Elena Levantini; Claudia S Huettner; Julie A Lekstrom-Himes; Koichi Akashi; Daniel G Tenen
Journal:  Immunity       Date:  2004-12       Impact factor: 31.745

6.  The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages.

Authors:  Hiromi Iwasaki; Shin-ichi Mizuno; Yojiro Arinobu; Hidetoshi Ozawa; Yasuo Mori; Hirokazu Shigematsu; Kiyoshi Takatsu; Daniel G Tenen; Koichi Akashi
Journal:  Genes Dev       Date:  2006-11-01       Impact factor: 11.361

7.  A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells.

Authors:  L M Scott; C I Civin; P Rorth; A D Friedman
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

8.  Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha.

Authors:  P Flodby; C Barlow; H Kylefjord; L Ahrlund-Richter; K G Xanthopoulos
Journal:  J Biol Chem       Date:  1996-10-04       Impact factor: 5.157

9.  Tissue-specific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein.

Authors:  E H Birkenmeier; B Gwynn; S Howard; J Jerry; J I Gordon; W H Landschulz; S L McKnight
Journal:  Genes Dev       Date:  1989-08       Impact factor: 11.361

10.  Granulopoiesis requires increased C/EBPα compared to monopoiesis, correlated with elevated Cebpa in immature G-CSF receptor versus M-CSF receptor expressing cells.

Authors:  Ou Ma; SunHwa Hong; Hong Guo; Gabriel Ghiaur; Alan D Friedman
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

View more
  11 in total

1.  Progression from the Common Lymphoid Progenitor to B/Myeloid PreproB and ProB Precursors during B Lymphopoiesis Requires C/EBPα.

Authors:  Hong Guo; Theresa Barberi; Rahul Suresh; Alan D Friedman
Journal:  J Immunol       Date:  2018-07-30       Impact factor: 5.422

2.  Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis.

Authors:  Wan Yee Leong; Hong Guo; Ou Ma; Hui Huang; Alan B Cantor; Alan D Friedman
Journal:  J Biol Chem       Date:  2015-11-23       Impact factor: 5.157

Review 3.  C/EBPα in normal and malignant myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

4.  The analysis of novel distal Cebpa enhancers and silencers using a transcriptional model reveals the complex regulatory logic of hematopoietic lineage specification.

Authors:  Eric Bertolino; John Reinitz
Journal:  Dev Biol       Date:  2016-03-03       Impact factor: 3.582

Review 5.  The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.

Authors:  E Ohlsson; M B Schuster; M Hasemann; B T Porse
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

6.  The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.

Authors:  Stacy Cooper; Hong Guo; Alan D Friedman
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

7.  Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia.

Authors:  J I Sive; S Basilico; R Hannah; S J Kinston; F J Calero-Nieto; B Göttgens
Journal:  Leukemia       Date:  2015-07-01       Impact factor: 11.528

Review 8.  Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.

Authors:  Ryan L Setten; Helen L Lightfoot; Nagy A Habib; John J Rossi
Journal:  Curr Pharm Biotechnol       Date:  2018       Impact factor: 2.837

9.  The regulatory control of Cebpa enhancers and silencers in the myeloid and red-blood cell lineages.

Authors:  Andrea Repele; Shawn Krueger; Tapas Bhattacharyya; Michelle Y Tuineau
Journal:  PLoS One       Date:  2019-06-10       Impact factor: 3.240

10.  In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis.

Authors:  Hong Guo; Stacy Cooper; Alan D Friedman
Journal:  PLoS One       Date:  2016-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.